Wu L, Li Y, Xu X-M, Zhu X
Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China.
Eur Rev Med Pharmacol Sci. 2022 Jan;26(2):346. doi: 10.26355/eurrev_202201_27855.
Correction to: European Review for Medical and Pharmacological Sciences 2019; 23 (21): 9418-9426-DOI: 10.26355/eurrev_201911_19435-PMID: 31773680, published online on 15 November 2019. After publication, the authors applied to change Figure 1E stating that "gastric cancer was observed from patients underlying response at Renmin Hospital of Wuhan University from March 2015 to March 2016. By the time of submission, the survival time of follow-up was only 2 years. From the 2-year follow-up data, we found that high expression of CIRC PRKCI was positively associated with a poor prognosis of GC patients". The authors claim that there is no serious change in the conclusion of the article. There are amendments to this paper. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/19435.
对《欧洲医学与药理学评论》2019年;23(21):9418 - 9426 - DOI: 10.26355/eurrev_201911_19435 - PMID: 31773680(于2019年11月15日在线发表)的更正。发表后,作者申请更改图1E,称“2015年3月至2016年3月在武汉大学人民医院对有反应的患者进行观察发现胃癌。在提交稿件时,随访生存时间仅为2年。从2年随访数据中,我们发现CIRC PRKCI的高表达与GC患者的不良预后呈正相关”。作者声称文章结论无重大变化。本文有修正内容。出版商对由此可能造成的不便表示歉意。https://www.europeanreview.org/article/19435